Læknablaðið - 01.02.2015, Blaðsíða 25

LÆKNAblaðið 2015/101 93
Y F i R l i T
1. Murphy DL, Timpano KR, Wheaton MG, Greenberg
BD, Miguel EC. Obsessive-compulsive disorder and its
related disorders: a reappraisal of obsessive-compulsive
spectrum concepts. Dialogues Clin Neurosci 2010; 12:
131-48.
2. Janet P. Les Obsessions et la Psychathenie. Alcan, Paris
1903.
3. Salzman L. Obsessional personality. Science House, New
York 1968.
4. Hudak R (Ed.). Clinical obsessive-disorders in adults
and children. 1st ed. Cambridge University Press,
Cambridge 2011.
5. Burgy M. Obsession in the strict sense: A helpful psycho-
pathological phenomenon in the differential diagnosis
between obsessive-compulsive disorder and schizop-
hrenia. Psychopathology 2007; 40: 102-10.
6. Oulis P, Konstantakopoulos G, Lykouras L,
Michalopoulo. Differential diagnosis of obsessive-
compulsive symptoms from delusions in schizophrenia:
A phenomenological approach. World G Psychiatry
2013; 22: 50-6.
7. Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-
compulsive disorder, Clinical review. BMJ 2006; 333:
424-9.
8. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike
MA, Rasmussen SA. DSM-IV field trial: obsessive
compulsive disorder. Am J Psychiatry 1995; 152: 90-6.
9. World health organization. International classification
of diseases and related health problems, tenth revision
(ICD-10). WHO, Genf 1992.
10. Hollander E. Obsessive-compulsive disorder: the hidden
epidemic. J Clin Psychiatry 1997; 58(Suppl 12):3-6.
11. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu
HG, Lee CK et al. The cross national epidemiology of
obsessive-compulsive disorder. The cross national group.
J Clin Psychiatry 1994; 55 Suppl: 5-10.
12. Ivarsson T, Melin K, Wallin K. Categorical and dimen-
sional aspects of co-morbidity in obsessive-compulsive
disorder. Eur Child Adolesc Psychiatry 2008; 17: 20-31.
13. American Psychiatric Association. Diagnostic and statisti-
cal manual of mental disorders, Fifth Edition (DSM-V).
Washington DC 2013.
14. National Institute for Health and Care Excellence.
Obsessive-compulsive disorder: core interventions in the
treatment of obsessive-compulsive disorder and body
dysmorphic disorder. NICE, London 2005.
15. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemio-
logy of obsessive compulsive disorder in the National
Comorbidity Survey Replication. Mol Psychiatry 2010;
15: 53-63.
16. Murray CJ, Lopez AD. Evidence based health policy –
lessons from the global burden of disease study. Science
1996; 274: 740-3.
17. Geller DA, Klier CM, Neugebauer R. Anxiety disorders
following miscarriage. J Clin Psychiatry 2001; 62: 432-8.
18. Williams KE, Koran LM. Obsessive-compulsive disorder
in pregnancy, the puerperium, and the premenstruum. J
Clin Psychiatry 1997; 58: 330-4.
19. Janowitz D, Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F,
Hochrein A, et al. Early onset obsessive-compulsive
disorder and associated comorbidity. Depress Anxiety
2009; 26: 1012-7.
20. Tukel R, Plolat A, Ozdemir O, Aksut D, Turksoy N.
Co-morbid conditions in obsessive-compulsive disorder.
Compr Psychiatry 2002; 43: 204-9.
21. Torresan RC, Ramos-Cerqueira AT, Shavitt RG, do
Rosario MC, de Mathis MA, Miguel MC et al. Symptom
dimensions, clinical course and comorbidity in men and
women with obsessive-compulsive disorder. Psychiatry
Res 2013; 30: 186-95.
22. Torres AR, Prince MJ, Bebbington BE, Brugha T, Bhugra
D, Farrel M. Am J Psychiatry 2006; 163: 1978-85.
23. Maia TV, Cooney RE, Peterson BS. The neural bases of
obsessive-compulsive disorder in children and adults.
Dev Psychopathol 2008; 20: 1251-83.
24. Pauls DL, Abramovitch, Rauch SL, Geller DA. Obsessive-
compulsive disorder: an integrative genetic and neurobio-
logical perspective. Nature Rev Neurosci 2014; 15: 410-24.
25. Fitzgerald KS, Welsh RC, Stern ER, Angstadt M, Hanna
GL, Abelson JL et al. Developmental alterations of frontal-
striatal-thalamic connectivity in obsessive-compulsive
disorder. J Am Acad Child Adolesc Psychiatry 2011; 50:
938-48.
26. Baxter LR. Neuroimaging studies of obsessive compulsive
disorder. Psychiatr Clin North Am 1992; 15: 871-84.
27. Saxena S, Brody Al, Schwartz JM, Baxter LR. Neuroimaging
and frontal-subcortical circuitry in obsessive-compulsive
disorder. Br J Psychiatry Suppl 1998; 35: 26-37.
28. Nikolaus S, Antke C, Beu M, Muller HW. Cortical GABA,
striatal dopamine and midbrain serotonin as the key
players in compulsive and anxiety disorders – results from
in vivo imaging studies. Rev Neurosci 2010; 21: 119-39.
29. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M,
Panzacchi A, et al. In vivo PET study 5HT(2A) serotonin
and D(2) dopamine dysfunction in drug-naïve obsessive-
compulsive disorder. Neuroimage 2008; 42: 306-14.
30. Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A,
Solbach C, et al. Reduced availability of serotonin tran-
sporters in obsessive-compulsive disorder correlates with
symptom severity – a (11C)DASP PET study. J Neural
Trans 2007; 114: 1603-9.
31. Insel TR, Mueller TA, Alterman I, Linnoila M, Murphy DL.
Obsessive-compulsive disorder and serotonin: is there a
connection? Biol Psychiatry 1985; 20: 1174-88.
32. Denys D, de Vries F, Cath D, Figee M, Vulink M,
Veltman DJ, et al. Dopaminergic activity in Tourette
syndrome and obsessive-compulsive disorder. Eur
Neuropsychopharmacol 2013; 23: 1423-31.
33. Nestadt G, Grados M, Samuels JF. Genetics of obsessive
compulsive disorder. Psychitr Clin North Am 2010; 33:
141-58.
34. Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin
studies in obsessive-compulsive disorder: a review. Twin
Res Hum Genet 2005; 8: 450-8.
35. Rachman S. A cognitive theory of obsessions. Behav Res
Ther 1997; 35: 793-802.
36. Salkovskis PM. Responsibility attitudes and interpreta-
tions are characteristic of obsessive-compulsive disorder.
Behav Res Ther 2000; 38: 347-72.
37. Rachman S, Hodgson R. Obsessions and compulsions.
Prentice Hall, Englewood Cliffs 1980.
38. Goodman WK, Price LH, Rasmussen LA, Mazure C,
Fleischmann RL, Hill CL, et al. The Yale-Brown obsessive-
compulsive scale I. Development, use and reliability. Arch
Gen Psychiatry 1989; 46: 1006-11.
39. Pallanti S, Quercioli L. Treatment refractory obsess-
ive-compulsive disorder: methodological issues,
operational definitions and therapeutic lines. Prog
Neuropsychopharmacol Biol Psychiatry 2006; 30: 400-12.
40. Ananth J. Treatment of obsessive-compulsive neurosis
with clomipramine (anafranil). J Int Med Res 1977; 5 Suppl
5: 38-41.
41. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman
L. Clomipramine treatment of obsessive-compulsive
disorder. I. A controlled clinical trial. Arch Gen Psychiatry
1980; 37: 1281-5.
42. Fineberg NA, Reghunandanan S, Brown A, Pampaloni.
Pharmacotherapy of obsessive-compulsive disorder: evi-
dence-based treatment and beyond. Aust N Z J Psychiatry
2013; 47: 121-41.
43. Pittenger C, Bloch MH. Pharmacological treatment of
obsessive-compulsive disorder. Psychiatr Clin North Am
2014; 37: 375-91.
44. Bandelow B. The medical treatment of obsessive-compul-
sive disorder and anxiety. CNS Spectr 2008; 13(Suppl
14): 37-46.
45. FDA drug safety communication: Revised recomm-
endations for Celexa (citalopram hydrobromide) related
to a potential risk of abnormal heart rhythms with
high doses. fda.gov/drugs/drugsafety/ucm297391.htm -
nóvember 2014.
46. McDougle CJ, Goodman WK, Price LH. The pharma-
cotherapy of obsessive-compulsive disorder.
Pharmacopsychiatry 1993; 26 (Suppl 1): 24-9.
47. Goddard A, Shin YW. Augmentation of serotonin reup-
take inhibitors in the treatment of obsessive-compulsive
disorder. In: Hudak R, Dougherty DD (Eds.). Clinical
obsessive-disorders in adults and children. 1st ed.
Cambridge University Press, Cambridge 2011: 49-60.
48. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS.
Combination treatment with clomipramine and selective
serotonin reuptake inhibitors for obsessive-compulsive
disorder in children and adolescents. J Child Adolesc
Psychopharmacol 1998; 8: 61-7.
49. Matsunaga H, Kiriike N, Matsui T, Oya K, Iwasaki Y.
Obsessive-compulsive disorder with poor insight. Compr
Psychiatry 2002; 43: 150-7.
50. Maher AR, Theodore G. Summary of the comparative
effectiveness review on off-label use of atypical antip-
sychotics. J Manag Care Pharm 2012; 18(5 SupplB): 1-20.
51. Kellner M. Drug treatment of obsessive-compulsive
disorder. Dialogues Clin Neurosci 2010; 12: 187-97.
52. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R,
Franklin ME, et al. Randomized, placebo-controlled trial
of exposure and ritual prevention, clomipramine and their
combination in the treatment of obsessive-compulsive
disorder. Am J Psychiatry 2005; 162: 151-61.
53. Franklin ME, Abramowitz JS, Kozak MJ, Levitt JT, Foa
EB. Effectiveness of exposure and ritual prevention for
obsessive-compulsive disorder: randomized compared
with nonrandomized samples. J Consult Clin Psychol
2000; 68: 594-602.
54. Marks I. Exposure therapy for phobias and obsessive-
compulsive disorders. Hosp Pract 1979; 14: 101-8.
55. Mancebo MC, Eisen JL, Sibrava NJ, Dyck IR, Rasmussen
RA. Patient utilization of cognitive-behavioral therapy for
OCD. Behav Ther 2011; 42: 399-412.
56. Sighvatsson MB, Kristjansdottir H, Sigurdsson E,
Sigurdsson JF. Gagnsemi hugrænnar atferlismeðferðar við
lyndis- og kvíðaröskunum hjá fullorðnum. Læknablaðið
2011; 97: 613-9.
57. Foa EB, Simpson HB, Liebowitz MR, Powers MB,
Rosenfield D, Cahill SP et al. Six-month follow-up of
a randomized controlled trial augmenting serotonin
reuptake inhibitor treatment with exposure and ritual
prevention for obsessive-compulsive disorder. J Clin
Psychiatry 2013; 74: 464-9.
58. Abramowitz JS, Storch EA, Keeley M, Cordell E.
Obsessive-compulsive disorder with comorbid major
depression: what is the role of cognitive factors? Behav
Res Ther 2007; 45: 2257-67.
59. Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price
BH, Niremberg AA. Prospective long-term follow-up of
44 patients who received cingulectomy for obsessive-
compulsive disorder. Am J Psychiatry 2002; 159: 269-75.
60. Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-
based neurotherapeutics: stereotactic ablation and deep
brain stimulation for OCD. Neuropsychopharmacology
2010; 35: 317-36.
61. Jakubovski E, Diniz JB, Valerio C, Fossaluza V, Belotto-
Silva C, Gorenstein C, et al. Clinical predictors of long-
term outcome in obsessive-compulsive disorder. Depress
Anxiety 2013; 30: 763-7.
62. Abramowitz JS, Lackey GR, Wheaton MG. Obsessive-
compulsive symptoms: the contribution of experimental
beliefs and experiential avoidance. J Anxiety Disord 2009;
23: 160-6.
63. Glazier K, Calixte RM, Rothschild R, Pinto A. High rates
of OCD symptom misidentification by mental health
professionals. Ann Clin Psychiatry 2013; 25: 201-9.
Heimildir